Abstract:

The incidence of endometrial carcinoma has been increasing in recent years, and the age of onset is tends to younger. Most endometrial carcinomas are low-grade, early-stage endometrioid carcinomas (EECs) with a good prognosis. However, some patients with low-grade, early-stage EECs are prone to recurrence and have a poor prognosis. Early identification of these high-risk patients with EECs can help determine which patients need additional adjuvant therapy and closer follow-up. In recent years, CTNNB1 mutation has been considered as a potential risk factor for recurrence, which has independent prognostic value. But so far, there are no clear guidelines on whether adjuvant therapy is needed for low-grade and early-stage EECs patients with CTNNB1 mutation. Combined with a patient with an ⅠA stage, low-grade patient with CTNNB1 gene mutation in our hospital, this gene mutation is mainly discussed in order to improve clinicians′ further understanding of the prognosis and follow-up treatment of patients with such mutation.

Key words: Endometrial neoplasms, CTNNB1 gene, Mutation, Genetic testing, Therapy, Prognosis